Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. (HALO) generates news that spans drug delivery technology, clinical applications, strategic collaborations and corporate finance. As a biopharmaceutical company focused on subcutaneous administration of biologics, Halozyme’s announcements often highlight how its ENHANZE and Hypercon platforms are being integrated into partner therapies and new indications.
News items frequently cover collaboration and license agreements with global pharmaceutical and biotechnology companies. Examples include agreements with Takeda to use ENHANZE with vedolizumab and with Merus to develop a subcutaneous formulation of petosemtamab. These stories typically describe upfront payments, potential milestones and royalty structures, as well as the therapeutic areas targeted by ENHANZE-enabled products.
Another major category of HALO news involves regulatory milestones achieved by partner products that incorporate Halozyme technologies. Recent press releases describe U.S. Food and Drug Administration approvals for DARZALEX Faspro and RYBREVANT FASPRO, both co-formulated with ENHANZE, in multiple myeloma and EGFR-mutated non-small cell lung cancer. Such updates provide insight into how Halozyme’s platforms translate into commercial products and expanded indications.
Halozyme also issues updates on intellectual property and legal matters, including patent enforcement actions related to its MDASE portfolio and court decisions affecting subcutaneous formulations of other companies’ drugs. In addition, investors can follow corporate developments such as acquisitions, including the purchase of Elektrofi and its Hypercon technology, board appointments, executive transitions and participation in healthcare conferences.
For investors and industry observers, the HALO news feed offers a way to track the evolution of Halozyme’s partnership base, the progress of ENHANZE- and Hypercon-enabled products, and key events that may influence the company’s royalty outlook and strategic direction.
Halozyme Therapeutics (NASDAQ: HALO) announced that Dr. Helen Torley, CEO, will present virtually at the 40th Annual J.P. Morgan Health Care Conference on January 10, 2022, at 7:30 a.m. PT. The conference runs from January 10-13, 2022. Interested parties can access the presentation via the Investors section of Halozyme's website. Halozyme specializes in biopharmaceutical solutions, particularly its ENHANZE® technology, which enhances drug delivery efficiency and has reached over 500,000 patients globally.
Halozyme Therapeutics (NASDAQ: HALO) has appointed Mark Snyder as the new senior vice president, general counsel, chief compliance officer, and corporate secretary, effective January 3, 2022. Snyder succeeds Masaru Matsuda, who is leaving for another opportunity. With nearly 30 years of legal and business experience, Snyder previously worked at Qualcomm, leading litigation strategies and managing legal operations. His appointment aims to enhance Halozyme's growth and shareholder value, as stated by CEO Helen Torley.
Halozyme Therapeutics has initiated a new share repurchase program, authorizing up to $750 million in buybacks over the next three years. This includes an accelerated share repurchase (ASR) of $150 million, with plans to acquire $250 million worth of shares by the end of 2022, contingent on market conditions. The program reflects Halozyme's commitment to a balanced capital allocation strategy, leveraging strong cash generation to return capital to investors while supporting growth initiatives.
Halozyme Therapeutics announced that Janssen Biotech received FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with Kyprolis (carfilzomib) and dexamethasone for adult patients with relapsed or refractory multiple myeloma. This marks the ninth indication for DARZALEX FASPRO. The approval is based on data from Janssen's PLEIADES Study, which achieved its primary endpoint of overall response rate. The product leverages Halozyme's ENHANZE technology, facilitating rapid treatment administration that may enhance patient experience.
Halozyme Therapeutics (NASDAQ: HALO) will participate in two upcoming investor conferences:
- 33rd Annual Piper Sandler Virtual Healthcare Conference on November 22, 2021, featuring Elaine Sun in an on-demand chat.
- Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, with Dr. Helen Torley representing the company in a virtual chat.
Presentations can be accessed via the investors section of Halozyme.com, with recordings available for six months.
Halozyme Therapeutics reported Q3 2021 financial results, with revenues reaching $115.8 million, up 77% year-over-year, driven by a 145% increase in royalty revenue. The company expects full-year royalty revenue to more than double from 2020. Operating income rose to $75.6 million from $40.3 million in Q3 2020. Q3 net income surged to $216.6 million, influenced by a $142.5 million tax benefit. Halozyme also repurchased 4.4 million shares for $189.7 million through Q3. Revenue guidance for 2021 is now set between $430 million and $445 million.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will host its Q3 2021 financial update on November 2 at 4:30 p.m. ET. CEO Dr. Helen Torley will lead the call, following the release of Q3 financial results for the period ending September 30, 2021. Interested investors can register for the call via Halozyme's website. The company's innovative ENHANZE® technology has aided over 500,000 patients through collaborations with leading pharmaceutical firms, enhancing treatment efficiency. A recording will be available post-call for those unable to attend.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that its CFO, Elaine Sun, will present at the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021, at 1:20 p.m. ET. An audio-only link for the presentation will be available in the "Investors" section of the Halozyme website, with a recording accessible for six months post-event. Halozyme specializes in biopharmaceutical solutions to enhance patient experiences and outcomes, leveraging its ENHANZE® technology to reduce treatment times significantly. The company's partnerships with major pharmaceutical firms play a key role in its growth.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will have Dr. Helen Torley, CEO, present at the Wells Fargo 2021 Virtual Healthcare Conference on September 10, 2021, at 10:40 a.m. ET. An audio link to the presentation will be available on Halozyme's website, with a recording accessible for six months post-event. Halozyme specializes in biopharmaceuticals, aiming to enhance patient experiences through innovative solutions like the ENHANZE® technology, drastically reducing treatment times. The company collaborates with major pharmaceutical firms, providing its technology across global markets.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported strong financial results for Q2 2021, with revenue reaching $136.5 million, up from $55.2 million in Q2 2020, largely driven by $60 million in milestone revenues. The company announced a collaboration with ViiV Healthcare for its ENHANZE® technology, raising its 2021 revenue guidance to $425-$445 million. The net income for Q2 was $91.5 million, reflecting significant growth. Additionally, Halozyme repurchased 1 million shares for $48.8 million during the quarter, enhancing shareholder value.
FAQ
What is the current stock price of Halozyme Thrp (HALO)?
What is the market cap of Halozyme Thrp (HALO)?
